Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury
Identifieur interne : 000246 ( Main/Exploration ); précédent : 000245; suivant : 000247Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury
Auteurs : RBID : ISTEX:259_1993_Article_BF00171011.pdfEnglish descriptors
- KwdEn :
Abstract
To test iodine-125 labelled low-density lipoprotein (125I-LDL), polyclonal indium-111 labelled immunoglobulin G (111In-IgG) and iodine-125 labelled endothelin-1 uptake in metabolically active atheromatous plaques after arterial wall injury, we performed balloon de-endothelialization of carotid arteries or abdominal aortas in 24 New Zealand male rabbits which were fed with a normal diet (n=14) or a hypercholesterolaemic diet (n=10) after surgery. Six weeks later the animals were injected with 200 μCi of (125I-LDL), and/or with 100 μCi of 111In-IgG or with 9 μCi of 125I-endothelin-1. Forty-eight hours later the animals were sacrificed. Carotid arteries and aortas were removed, counted and fixed for autoradiography and light microscopy examination. Contralateral carotid arteries and thoracic aortas served as controls.Significant 111In-IgG uptake was observed in the injured arteries at autoradiography, with localization mainly in the healing edges, and at well counting. The percentage of the injected dose per gram (%D.inj/g) was 0.0188±0.06 versus 0.0059±0.003 in controls (P< 0.05). There was no difference in 111In-IgG uptake between arteries with injury alone and those with active atheroma formation at the site of the injury. Significant (125I-LDL), uptake was observed only when lipid deposition was present at light microscopy (%D.inj/g of 0.0024±0.0005 vs 0.0010±0.0003 in controls, P < 0.05). 125I-endothelin-1 accumulation was observed in four of five injured aortas both at autoradiography, with diffuse localization, and at well counting (%D.inj/g of 0.0012±0.0004 in the abdominal aortas vs 0.0008±0.0003 in the thoracic aortas).Polyclonal IgG may accumulate in injured arteries without active atheroma formation. Inflammatory reaction at the site of the injury may cause 111In-IgG uptake independently of atheromatous plaque formation. LDL accumulation takes place only with active atheroma formation at the site of the injury. Use of labelled peptides such as endothelin-1 may provide further insight into the mechanisms of atheromatous plaque formation.
DOI: 10.1007/BF00171011
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury</title>
<author><name>L. Prat</name>
<affiliation wicri:level="1"><mods:affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>G. Torres</name>
<affiliation wicri:level="1"><mods:affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>I. Carrió</name>
<affiliation wicri:level="1"><mods:affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>M. Roca</name>
<affiliation wicri:level="1"><mods:affiliation>Nuclear Medicine Department, Hospital Universitari de Bellvitge, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Nuclear Medicine Department, Hospital Universitari de Bellvitge, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>V. Riambau</name>
<affiliation wicri:level="1"><mods:affiliation>Cardiovascular Surgery Department, Hospital Clinic, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Cardiovascular Surgery Department, Hospital Clinic, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>L. Berná</name>
<affiliation wicri:level="1"><mods:affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>M. Estorch</name>
<affiliation wicri:level="1"><mods:affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>I. Ferrer</name>
<affiliation wicri:level="1"><mods:affiliation>Nuclear Medicine Department, Hospital Universitari de Bellvitge, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Nuclear Medicine Department, Hospital Universitari de Bellvitge, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author><name>C. Garcia</name>
<affiliation wicri:level="1"><mods:affiliation>Vascular Surgery Department, Hospital de Sant Pau, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Vascular Surgery Department, Hospital de Sant Pau, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="RBID">ISTEX:259_1993_Article_BF00171011.pdf</idno>
<date when="1993">1993</date>
<idno type="doi">10.1007/BF00171011</idno>
<idno type="wicri:Area/Main/Corpus">000E27</idno>
<idno type="wicri:Area/Main/Curation">000E27</idno>
<idno type="wicri:Area/Main/Exploration">000246</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Atheromatous plaque</term>
<term>Atherosclerosis</term>
<term>Balloon de-endothelialization</term>
<term>Indium-111 labelled immunoglobulin Gc</term>
<term>Iodine-125 labelled endothelin-1</term>
<term>Iodine-125 labelled low-density lipoprotein</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">To test iodine-125 labelled low-density lipoprotein (125I-LDL), polyclonal indium-111 labelled immunoglobulin G (111In-IgG) and iodine-125 labelled endothelin-1 uptake in metabolically active atheromatous plaques after arterial wall injury, we performed balloon de-endothelialization of carotid arteries or abdominal aortas in 24 New Zealand male rabbits which were fed with a normal diet (n=14) or a hypercholesterolaemic diet (n=10) after surgery. Six weeks later the animals were injected with 200 μCi of (125I-LDL), and/or with 100 μCi of 111In-IgG or with 9 μCi of 125I-endothelin-1. Forty-eight hours later the animals were sacrificed. Carotid arteries and aortas were removed, counted and fixed for autoradiography and light microscopy examination. Contralateral carotid arteries and thoracic aortas served as controls.Significant 111In-IgG uptake was observed in the injured arteries at autoradiography, with localization mainly in the healing edges, and at well counting. The percentage of the injected dose per gram (%D.inj/g) was 0.0188±0.06 versus 0.0059±0.003 in controls (P< 0.05). There was no difference in 111In-IgG uptake between arteries with injury alone and those with active atheroma formation at the site of the injury. Significant (125I-LDL), uptake was observed only when lipid deposition was present at light microscopy (%D.inj/g of 0.0024±0.0005 vs 0.0010±0.0003 in controls, P < 0.05). 125I-endothelin-1 accumulation was observed in four of five injured aortas both at autoradiography, with diffuse localization, and at well counting (%D.inj/g of 0.0012±0.0004 in the abdominal aortas vs 0.0008±0.0003 in the thoracic aortas).Polyclonal IgG may accumulate in injured arteries without active atheroma formation. Inflammatory reaction at the site of the injury may cause 111In-IgG uptake independently of atheromatous plaque formation. LDL accumulation takes place only with active atheroma formation at the site of the injury. Use of labelled peptides such as endothelin-1 may provide further insight into the mechanisms of atheromatous plaque formation.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="f62e8532e6813fdb15c2a348e050a9b6546652c5"><titleInfo lang="eng"><title>Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury</title>
</titleInfo>
<name type="personal"><namePart type="given">L.</namePart>
<namePart type="family">Prat</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">G.</namePart>
<namePart type="family">Torres</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">I.</namePart>
<namePart type="family">Carrió</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">M.</namePart>
<namePart type="family">Roca</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Nuclear Medicine Department, Hospital Universitari de Bellvitge, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">V.</namePart>
<namePart type="family">Riambau</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Cardiovascular Surgery Department, Hospital Clinic, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">L.</namePart>
<namePart type="family">Berná</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">M.</namePart>
<namePart type="family">Estorch</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Nuclear Medicine Department, Hospital de Sant Pau, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">I.</namePart>
<namePart type="family">Ferrer</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Nuclear Medicine Department, Hospital Universitari de Bellvitge, Barcelona, Spain</affiliation>
</name>
<name type="personal"><namePart type="given">C.</namePart>
<namePart type="family">Garcia</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Vascular Surgery Department, Hospital de Sant Pau, Barcelona, Spain</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Article</genre>
<genre>Original Paper</genre>
<originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher>
<dateCreated encoding="w3cdtf">1993-05-08</dateCreated>
<dateValid encoding="w3cdtf">2004-07-01</dateValid>
<copyrightDate encoding="w3cdtf">1993</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">To test iodine-125 labelled low-density lipoprotein (125I-LDL), polyclonal indium-111 labelled immunoglobulin G (111In-IgG) and iodine-125 labelled endothelin-1 uptake in metabolically active atheromatous plaques after arterial wall injury, we performed balloon de-endothelialization of carotid arteries or abdominal aortas in 24 New Zealand male rabbits which were fed with a normal diet (n=14) or a hypercholesterolaemic diet (n=10) after surgery. Six weeks later the animals were injected with 200 μCi of (125I-LDL), and/or with 100 μCi of 111In-IgG or with 9 μCi of 125I-endothelin-1. Forty-eight hours later the animals were sacrificed. Carotid arteries and aortas were removed, counted and fixed for autoradiography and light microscopy examination. Contralateral carotid arteries and thoracic aortas served as controls.Significant 111In-IgG uptake was observed in the injured arteries at autoradiography, with localization mainly in the healing edges, and at well counting. The percentage of the injected dose per gram (%D.inj/g) was 0.0188±0.06 versus 0.0059±0.003 in controls (P< 0.05). There was no difference in 111In-IgG uptake between arteries with injury alone and those with active atheroma formation at the site of the injury. Significant (125I-LDL), uptake was observed only when lipid deposition was present at light microscopy (%D.inj/g of 0.0024±0.0005 vs 0.0010±0.0003 in controls, P < 0.05). 125I-endothelin-1 accumulation was observed in four of five injured aortas both at autoradiography, with diffuse localization, and at well counting (%D.inj/g of 0.0012±0.0004 in the abdominal aortas vs 0.0008±0.0003 in the thoracic aortas).Polyclonal IgG may accumulate in injured arteries without active atheroma formation. Inflammatory reaction at the site of the injury may cause 111In-IgG uptake independently of atheromatous plaque formation. LDL accumulation takes place only with active atheroma formation at the site of the injury. Use of labelled peptides such as endothelin-1 may provide further insight into the mechanisms of atheromatous plaque formation.</abstract>
<subject lang="eng"><genre>Key words</genre>
<topic>Atheromatous plaque</topic>
<topic>Atherosclerosis</topic>
<topic>Indium-111 labelled immunoglobulin Gc</topic>
<topic>Iodine-125 labelled low-density lipoprotein</topic>
<topic>Iodine-125 labelled endothelin-1</topic>
<topic>Balloon de-endothelialization</topic>
</subject>
<relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title>
</titleInfo>
<titleInfo><title>European Journal of Nuclear Medicine</title>
<partNumber>Year: 1993</partNumber>
<partNumber>Volume: 20</partNumber>
<partNumber>Number: 12</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo><dateIssued encoding="w3cdtf">1993-12-01</dateIssued>
<copyrightDate encoding="w3cdtf">1993</copyrightDate>
</originInfo>
<subject usage="primary"><topic>Medicine & Public Health</topic>
<topic>Imaging / Radiology</topic>
<topic>Nuclear Medicine</topic>
</subject>
<identifier type="issn">0340-6997</identifier>
<identifier type="issn">Electronic: 1619-7089</identifier>
<identifier type="matrixNumber">259</identifier>
<identifier type="local">IssueArticleCount: 13</identifier>
<recordInfo><recordOrigin>Springer-Verlag, 1993</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF00171011</identifier>
<identifier type="matrixNumber">Art3</identifier>
<identifier type="local">BF00171011</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part><extent unit="pages"><start>1141</start>
<end>1145</end>
</extent>
</part>
<recordInfo><recordOrigin>Springer-Verlag, 1993</recordOrigin>
<recordIdentifier>259_1993_Article_BF00171011.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000246 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000246 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= *** parameter Area/wikiCode missing *** |area= IndiumV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:259_1993_Article_BF00171011.pdf |texte= Polyclonal 111In-IgG, 125I-LDL and 125I-endothelin-1 accumulation in experimental arterial wall injury }}
This area was generated with Dilib version V0.5.81. |